Janus Henderson Group Portfolio holdings
Janus Henderson Group, formed in 2017 through the merger of Janus Capital Group (founded 1969) and Henderson Group (founded 1934), is a global asset management firm headquartered in London, managing over $350 billion in assets as of late 2024 for institutional, retail, and high-net-worth clients. With a strong presence in the U.S., Europe, and Asia-Pacific, the firm offers a wide range of investment products, including equities, fixed income, multi-asset, and alternative strategies, often blending active management with research-driven insights. Known for its equity expertise from Janus’s growth-focused heritage and Henderson’s European fixed-income strengths, Janus Henderson serves clients through mutual funds, ETFs, and bespoke portfolios, emphasizing risk-adjusted returns and ESG integration. Led by CEO Ali Dibadj since 2022, the publicly traded firm (NYSE: JHG) continues to refine its strategy amid competitive pressures, maintaining a foothold in key markets worldwide.
Top Buys
| 1 | +$1.74B | |
| 2 | +$1.16B | |
| 3 | +$501M | |
| 4 |
Palantir
PLTR
|
+$451M |
| 5 |
DoorDash
DASH
|
+$411M |
Top Sells
| 1 | +$1.22B | |
| 2 | +$866M | |
| 3 | +$690M | |
| 4 |
DAY
Dayforce
DAY
|
+$576M |
| 5 |
Workday
WDAY
|
+$531M |
Sector Composition
| 1 | Technology | 32.5% |
| 2 | Healthcare | 20.49% |
| 3 | Industrials | 11.17% |
| 4 | Consumer Discretionary | 9.27% |
| 5 | Communication Services | 8.49% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
351
iShares MSCI Emerging Markets ex China ETF
EMXC
$23B
| $68.5M | 0.03% |
+870,965
|
|
||
|
DFTX
352
Definium Therapeutics
DFTX
$2.53B
| $67.2M | 0.03% |
3,556,041
+1,144,345
|
|
||
|
SPYM
353
State Street SPDR Portfolio S&P 500 ETF
SPYM
$143B
| $66.8M | 0.03% |
872,415
-62,735
|
|
||
|
BCAX
354
Bicara Therapeutics
BCAX
$1.33B
| $66.4M | 0.03% |
3,339,218
+692,933
|
|
||
355
Public Storage
PSA
$56.9B
| $65M | 0.03% |
239,768
-19,046
|
|
||
356
ATS Corp
ATS
$2.56B
| $64.5M | 0.03% |
2,297,214
+1,435,375
|
|
||
357
Frontdoor
FTDR
$4.71B
| $64.5M | 0.03% |
1,220,768
+317,995
|
|
||
358
MoonLake Immunotherapeutics
MLTX
$1.29B
| $64.3M | 0.03% |
3,451,628
+1,355,640
|
|
||
359
TechnipFMC
FTI
$27.9B
| $64M | 0.03% |
924,838
+205,637
|
|
||
360
Kirby Corp
KEX
$7.46B
| $63.8M | 0.03% |
480,015
-78,285
|
|
||
361
New York Times
NYT
$11.8B
| $63.7M | 0.03% |
761,118
+177,045
|
|
||
362
iShares Core MSCI Emerging Markets ETF
IEMG
$152B
| $63.7M | 0.03% |
+912,578
|
|
||
363
Simon Property Group
SPG
$69B
| $63.2M | 0.03% |
338,772
+285,426
|
|
||
364
Blue Bird Corp
BLBD
$2.17B
| $62.7M | 0.03% |
1,102,335
+324,710
|
|
||
365
Crane Co
CR
$11.3B
| $61.8M | 0.03% |
361,270
+71,086
|
|
||
366
Andersons Inc
ANDE
$2.53B
| $61.8M | 0.03% |
860,942
+223,600
|
|
||
367
Neurocrine Biosciences
NBIX
$16.2B
| $61.5M | 0.03% |
466,977
+7,801
|
|
||
|
DMRA
368
Damora Therapeutics
DMRA
$1.24B
| $61.4M | 0.03% |
2,362,696
+2,360,957
|
|
||
369
Lazard
LAZ
$4.07B
| $60.8M | 0.03% |
1,431,358
+48,607
|
|
||
370
Alkami Technology
ALKT
$1.61B
| $60.4M | 0.03% |
3,855,334
+646,898
|
|
||
371
Collegium Pharmaceutical
COLL
$1.13B
| $60.4M | 0.03% |
1,825,651
+377,073
|
|
||
372
Blackbaud
BLKB
$1.3B
| $60.1M | 0.03% |
1,555,833
+58,806
|
|
||
373
Delta Air Lines
DAL
$50.2B
| $60.1M | 0.03% |
903,471
-185,935
|
|
||
374
Medpace
MEDP
$13.3B
| $60M | 0.03% |
124,954
+21,709
|
|
||
375
Erasca
ERAS
$4.16B
| $60M | 0.03% |
+3,710,966
|
|